Gossamer Bio (GOSS) Assets Average (2019 - 2026)
Gossamer Bio (GOSS) posted quarterly Assets Average of $150.6 million for Q1 2026, down 49.46% year-over-year from $297.9 million in Q1 2025, and down 20.97% quarter-over-quarter from $190.5 million in Q4 2025.
Gossamer Bio (GOSS) Assets Average (2019 - 2026) Analysis & Trends
Gossamer Bio's Assets Average history runs 8 years deep, the most recent figure standing at $150.6 million for Q1 2026.
- In Q1 2026, Assets Average fell 49.46% year-over-year to $150.6 million; the TTM figure through Mar 2026 stood at $150.6 million (down 49.46% YoY), while the FY2025 annual figure was $243.8 million, down 22.27% from the prior year.
- Assets Average for Q1 2026 stood at $150.6 million, down from $190.5 million in the prior quarter.
- The five-year high for Assets Average was $362.2 million in Q3 2024, with the low at $150.6 million in Q1 2026.
- The 5-year median for Assets Average is $284.7 million (2022), against an average of $272.7 million.
- The sharpest annual moves came in 2024 and 2026: Assets Average surged 57.55% in 2024, then slumped 49.46% in 2026.
- Gossamer Bio's Assets Average stood at $298.0 million in 2022, then climbed by 10.71% to $329.9 million in 2023, then gained by 0.96% to $333.1 million in 2024, then sank by 42.8% to $190.5 million in 2025, then dropped by 20.97% to $150.6 million in 2026.
- Business Quant data shows GOSS's Assets Average at $150.6 million in Q1 2026, $190.5 million in Q4 2025, and $224.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | 102.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102.88 Mn |
| Mar 31, 2026 | 150.57 Mn |
| Dec 31, 2025 | 190.53 Mn |
| Sep 30, 2025 | 224.87 Mn |
| Jun 30, 2025 | 260.76 Mn |
| Mar 31, 2025 | 297.94 Mn |
| Dec 31, 2024 | 333.09 Mn |
| Sep 30, 2024 | 362.16 Mn |
| Jun 30, 2024 | 316.40 Mn |
| Mar 31, 2024 | 285.64 Mn |
| Dec 31, 2023 | 329.92 Mn |
| Sep 30, 2023 | 264.84 Mn |
| Jun 30, 2023 | 200.83 Mn |
| Mar 31, 2023 | 246.18 Mn |
| Dec 31, 2022 | 297.99 Mn |
| Sep 30, 2022 | 284.69 Mn |
| Jun 30, 2022 | 270.26 Mn |
| Mar 31, 2022 | 319.17 Mn |
| Dec 31, 2021 | 365.35 Mn |
| Sep 30, 2021 | 409.77 Mn |